Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).

Details

Language :

English

ISSN :

00903493

Volume :

50

Issue :

12

Database :

Complementary Index

Journal :

Critical Care Medicine

Publication Type :

Academic Journal

Accession number :

160281568

Full Text :

https://doi.org/10.1097/CCM.0000000000005683